BCA
FLGT icon

Berman Capital Advisors’s Fulgent Genetics FLGT Stock Holding History

Berman Capital Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$13K Buy
+150
New +$13.6K ﹤0.01% 1097

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Berman Capital Advisors's FLGT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Fulgent Genetics (FLGT) in Q3 2021: 150 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1097 among its holdings.

268 funds tracked by Wall St. Rank hold FLGT as of Q3 2021.

  • Berman Capital Advisors held 150 shares of Fulgent Genetics worth $13K as of Q3 2021.
  • Fulgent Genetics was a new Berman Capital Advisors position in Q3 2021.
  • Fulgent Genetics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1097 holding.
  • 268 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.